Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

Status:
Active, not recruiting

Trial end date:
2022-09-10

Target enrollment:

Participant gender:

The purpose of the study is to assess the safety and efficacy of JNJ-64304500 in participants with moderately to severely active Crohn's disease.

Phase 2

Janssen Research & Development, LLC

Ustekinumab